Citations

Showing 10 of 108083 citations.

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)
Tandon, Nidhi , Sidana, Surbhi , Lacy, Martha Q. , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hwa, Yi L. , Hobbs, Miriam, Kapoor, Prashant , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Lust, John A., Russell, Stephen J. , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Fonder, Amie L, Hwa, Yi Lisa, Gonsalves, Wilson , Leung, Nelson , Go, Ronald S , Russell, Stephen J , Sidana, Surbhi , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | September 27, 2017 | Volume: 93 | Issue: 1 | Pages: 17-22

10.1002/ajh.24919 | PMID 28960427 Get It

AbstractAchievement of a normal FLC ratio (FLCr) following treatment indicates hematologic response and suggests better outcomes in light chain amyloidosis (AL). We examined if elevated involved free light chain (hiFLC) impacts outcomes in patients achieving normal FLCr. We retrospectively analyzed 345 AL patients who were diagnosed within a 10‐year period (2006‐2015) and had 2 consecutive normal FLCr values after 1st line treatment. Among these, patients with hiFLC at 1st reading of normal FLCr (hiFLC1; n = 166; 48.1%) were compared to those who did not (n = 179; 51.9%). Patients with AL who have hiFLC1 after initial therapy had higher rates of multi‐organ involvement (63.3 vs 46.4%; P = .002) and patients in advanced Mayo stage (42.9 vs 32.2%; P = .04) at diagnosis. The median progression free survival [PFS; 38.2 (95%CI; 26.4, 55.4) vs 67.1 (95%CI; 55.8, 88) months; P = .0002] and overall survival [OS; 94.4 (95%CI; 78, 107.1) vs not reached (NR, 95%CI; 116.1, NR) months; P < .0001] were lower in those who had hiFLC1. A more stringent comparison for patients with 2 consecutive hiFLC (hIFLC2; n = 111; 32.2%) versus not (n = 2234; 67.8%) showed consistent results [PFS; 27.1 (95%CI; 23, 53.8) vs 63.3 (95%CI; 55.4, 77) months; P < .0001 and OS; 78 (95% CI; 54.6, 98.8) vs NR (95%CI; NR, NR); P < .0001]. This poor prognostic impact of hiFLC on survival was independent of serum creatinine, Mayo stage, negative immunofixation status and inclusion of transplant in initial therapy on multivariate analysis. Hence, persistent elevation of iFLC predicts poor prognosis even among patients achieving normal ratio after initial therapy in AL.
A baseline drift detrending technique for fast scan cyclic voltammetry
DeWaele, Mark, Park, Cheonho , Kang, Yu Min , Shin, Hojin , Bennet, Kevin E. , Lee, Kendall H. , Jang, Dong Pyo , Oh, Yoonbae , Blaha, Charles D. , Kim, In Young

Mayo Clinic

The Analyst | September 27, 2017 | Volume: 142 | Issue: 22 | Pages: 4317-4321

10.1039/c7an01465a | PMID 29063091 Get It

A simple, and yet robust, high pass filter is designed to remove non-linear background drift in fast scan cyclic voltammetry.
Effect of atrial fibrillation duration on plasma von Willebrand factor level
Wysokiński, Waldemar E. , Cohoon, Kevin P. , Konik, Ewa, Melduni, Rowlens M. , Ammash, Naser M., Asirvatham, Samuel J. , McBane, Robert D. , Konik, Ewa A, Wysokinski, Waldemar , McBane, Robert , Asirvatham, Samuel J

Mayo Clinic

European Journal of Haematology | September 27, 2017 | Volume: 99 | Issue: 6 | Pages: 569-576

10.1111/ejh.12975 | PMID 28952167 Get It

AbstractAimsvon Willebrand factor (VWF) is an independent risk factor for adverse events in patients with non‐valvular atrial fibrillation (NVAF). However, it is unclear if VWF level remains elevated and predictive of stroke during entire course of NVAF.Methods and ResultsIn order to determine if VWF is a time‐dependent blood variable, VWF antigen measured by latex immunoassay in 425 NVAF patients and 100 controls with normal sinus rhythm (NSR) was analyzed according to NVAF duration (<1 month: n = 76, 1‐12 months: n = 98, and >12 months: n = 251). The mean VWF antigen level in NVAF patients with <1‐month duration (167 ± 59%) was not different compared to those with 1‐12 months (157 ± 50%, P = .24) and >12 months duration (156 ± 54%, P = .11) but higher compared to NSR controls (143 ± 48%, P = .003). Higher VWF level correlated with higher CHADS2 scores and with progressing intensity of blood stasis in the left atrium and thrombus formation in all three time periods of atrial fibrillation duration. Patients not treated with warfarin had VWF 30% higher in the first month compared to following months.Conclusionsvon Willebrand Factor is steadily elevated throughout the course of dysrhythmia in NVAF patients treated with warfarin and in those with higher intensity of left atrium blood stasis.
Plasma sphingolipids and depressive symptoms in coronary artery disease
Dinoff, Adam, Saleem, Mahwesh, Herrmann, Nathan , Mielke, Michelle M. , Oh, Paul , Venkata, Swarajya Lakshmi Vattem, Lanctôt, Krista L. , Lanctôt, Krista L , Mielke, Michelle M , Haughey, Norman J.

Mayo Clinic

Brain and Behavior | September 27, 2017 | Volume: 7 | Issue: 11 | Pages: No page available

10.1002/brb3.836 | PMID 29201542 Get It

AbstractBackgroundDepression is highly prevalent in individuals with coronary artery disease (CAD) and increases the risk of future cardiac events and mortality. Sphingolipids have been implicated in the pathophysiology of both CAD and depression. This study assessed the association between plasma sphingolipid concentrations and depressive symptoms in CAD subjects.MethodsDepressive symptoms were measured using the depression subscale of the self‐reported Hospital Anxiety and Depression Scale (HADS). Sphingolipid concentrations were measured from fasting plasma samples using high‐performance liquid chromatography‐coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Linear regression models were used to assess associations between log‐transformed concentrations of plasma sphingolipids and depressive symptoms.ResultsA total of 111 CAD patients (mean (SD) age = 63.6 ± 6.4, 84.7% male) were included. In linear regression analyses, higher plasma concentrations of ceramides C16:0 (β = 0.204, p = .026) and C18:0 (β = 0.209, p = .023) and sphingomyelin SM18:1 (β = 0.210, p = .024) were significantly associated with higher HADS depression subscale score after adjusting for covariates.ConclusionSphingolipids, in particular the ceramide species C16:0 and C18:0 and the sphingomyelin species SM18:1, may be implicated in the pathophysiology of depression in CAD. The association between plasma sphingolipid concentrations and depression should be further examined in CAD patients and in other populations.
Building Blocks of Structural Intervention
Alkhouli, Mohamad , Maor, Elad , Panaich, Sidakpal , Alli, Oluseun , Coylewright, Megan , Reeder, Guy S., Sandhu, Gurpreet S. , Holmes, David R. , Malouf, Joseph F., Eleid, Mackram F. , Rihal, Charanjit S. , Raphael, Claire E. , Panaich, Sidakpal S, Nishimura, Rick, Malouf, Joseph, Cabalka, Allison, Panaich, Sidakpal S , Maor, Elad , Alkhouli, Mohamad , Nishimura, Rick A. , Cabalka, Allison K. , Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | September 27, 2017 | Volume: 10 | Issue: 10 | Pages: No page available

10.1161/circinterventions.117.005686 | PMID 28951397 Get It

Structural heart disease is a rapidly evolving field, and approaches to procedural training are not standardized. We describe a novel modular approach to procedural training that considers each procedure as a series of building blocks that may be taught and assessed separately. Ten key structural heart disease building blocks can be identified, which, when combined with the cognitive skills of structural intervention and device-specific training, allow appropriate planning and implementation of structural procedures. Structural procedures require careful navigation of the aorta, left atrium, and right heart, including detailed understanding of relational anatomy. Component blocks include large bore vascular access, navigation within the left atrium, occlusion, snaring, and 3-dimensional relational anatomy. These building blocks also provide the foundation for new procedures through innovative use of the skill sets and devices to approach new clinical problems. The addition of device-specific training may be provided via proctoring and industry support. Using this approach, competency in less common procedures may be achieved and maintained. We discuss each building block in detail, approaches specific to the structural heart disease patient, the need for cross-discipline training, and empirical recommendations for training using this approach. We postulate that this new paradigm may be the preferred approach for training and assessment of structural heart disease interventional skills.
Arthritis Progression on Serial MRIs Following Diagnosis of Medial Meniscal Posterior Horn Root Tear
Johnson, Nick, Mohan, Rohith , Littrell, Laurel A. , Collins, Mark S., Krych, Aaron J. , Johnson, Nick R., Krych, Aaron J , Hevesi, Mario , Stuart, Michael J.

Mayo Clinic

The Journal of Knee Surgery | September 26, 2017 | Volume: 31 | Issue: 07 | Pages: 698-704

10.1055/s-0037-1607038 | PMID 28950387 Get It

AbstractMedial meniscus posterior root tears (MMPRTs) are a significant source of pain and dysfunction. The purpose of this study was to evaluate changes in the medial compartment of the knee over time following the diagnosis of a MMPRT on MRI. A retrospective review of the institutional database was performed for patients with an initial MRI diagnosis of a MMPRT. Patients were included if they had a subsequent follow-up MRI on the same knee. Patients with surgical intervention, including debridement or repair, were excluded. MRIs were evaluated by two board-certified musculoskeletal radiologists. MMPRTs were defined using the LaPrade classification, and the medial compartment articular cartilage was graded using the modified Outerbridge classification. MRIs were reviewed for meniscus extrusion, subchondral bone edema, and insufficiency fractures. Patients were divided into two groups for the analysis to account for differences in MRI time intervals. Group 1 had a follow-up MRI within 12 months of initial imaging (subacute group) and Group 2 had a follow-up MRI greater than 12 months after initial imaging (chronic group). Forty-one knees and 82 MRIs were analyzed, including 20 knees/40 MRIs (13 females, 7 males) in the subacute group and 21 knees/42 MRIs (14 females, 7 males) in the chronic group. Subacute patients had a mean age of 59.5 ± 8.8 years and a mean interval of 4.8 ± 2.6 months between MRIs compared with 53.6 ± 11.0 years and 38.2 ± 20.8 months, respectively, for the chronic group. Meniscal extrusion, femoral modified Outerbridge grade, and tibial modified Outerbridge grade worsened between initial and final MRI in both groups (p < 0.05). In both groups, there were no significant differences between initial and final MRIs with regard to the LaPrade classification, insufficiency fracture, or subchondral cysts of the tibia. Progressive meniscus extrusion and medial compartment articular cartilage degeneration were seen in patients with MMPRTs within a year from diagnosis.
The challenges of implementing pharmacogenomic testing in the clinic
Moyer, Ann M. , Caraballo, Pedro J. , Caraballo, Pedro J

Mayo Clinic

Expert Review of Pharmacoeconomics & Outcomes Research | September 26, 2017 | Volume: 17 | Issue: 6 | Pages: 567-577

10.1080/14737167.2017.1385395 | PMID 28949250 Get It

Early Detection of Pancreatic Cancer
Kenner, Barbara , Go, Vay Liang W., Chari, Suresh T. , Goldberg, Ann, Rothschild, Laura J., Kenner, Barbara J, Chari, Suresh T

Mayo Clinic

Pancreas | September 26, 2017 | Volume: 46 | Issue: 10 | Pages: 1238-1241

10.1097/mpa.0000000000000939 | PMID 28953187 Get It

Abstract A diagnosis of pancreatic cancer is devastating owing to its poor prognosis, with a 5-year survival rate of only 9%. Currently, most individuals are diagnosed at a late stage when treatment options are limited. Early detection of pancreatic cancer provides the greatest hope for making substantial improvements in survival. The Kenner Family Research Fund in partnership with the American Pancreatic Association has sponsored a series of fora to stimulate discussion and collaboration on early detection of pancreatic cancer. At the first forum in 2014, “Early Detection of Sporadic Pancreatic Cancer Summit Conference,” a strategic plan was set forth by an international group of interdisciplinary scientific representatives and subsequently The Strategic Map for Innovation was generated. The current conference report is the third forum in the series, “Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers,” which was held in Boston, Massachusetts, on October 27, 2016. This report provides an overview of examples of innovative initiatives by industry and confirms the critical need for collaboration among industry, government, research institutions, and advocacy groups in order to make pancreatic cancer more easily detectable in its earlier stages, when it is more treatable.
A Case of Rituximab-Induced Necrotizing Fasciitis and a Review of the Literature
Abdulkareem, Abdullateef , D’Souza, Ryan S. , Shogbesan, Oluwaseun , Donato, Anthony A. , Donato, Anthony , D'Souza, Ryan S

Mayo Clinic

Case Reports in Hematology | September 26, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-5

10.1155/2017/6971027 | PMID 29082050 Get It

Necrotizing fasciitis is a fulminant soft tissue infection characterized by rapid progression and high mortality. Rituximab is a generally well-tolerated immunosuppresive medication used for B-cell malignancies and some rheumatological disorders. We report a case of a 69-year-old male with chronic lymphocytic leukemia who suffered necrotizing fasciitis of his left lower extremity secondary to Clostridium septicum 7 weeks after treatment with rituximab. Despite immediate intravenous antimicrobial therapy and emergent fasciotomy with extensive debridement, his hospital course was complicated by septic shock and he required an above-the-knee amputation. Physicians need to be aware of the possibility of necrotizing fasciitis in patients presenting with skin infections after rituximab therapy.
Reply
Marietta, Eric, Mangalam, Ashutosh K. , Taneja, Veena , Mangalam, Ashutosh, Taneja, Veena , Murray, Joseph A.

Mayo Clinic

Arthritis & Rheumatology | September 26, 2017 | Volume: 70 | Issue: 2 | Pages: 321-322

10.1002/art.40331 | PMID 28950432 Get It